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BRCA1 and BRCA2 mutations increase breast and ovarian cancer risks substantially enough to warrant risk reduction surgery, despite
variable risk estimates. Underlying this variability are methodological issues, and also complex genetic and nongenetic effects.
Although many modifying factors are unidentified, known factors can already be incorporated in individualised risk prediction.
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BRCA1 and BRCA2 were identified as genes mutated in hereditary
breast/ovarian cancer by genetic analysis in families with multiple
cases of these malignancies. In the following decade, as BRCA1 and
BRCA2 testing became more common in patients with a personal
or family history of cancer, numerous studies assessed cancer risks
in carriers of these mutations. These studies have resulted in
variable risk estimates, leading to difficulties in defining risk
figures that are clinically applicable to the individual patient.
However, they illuminated the complexities that underlie risk
prediction even in the context of a single gene with major effects
on cancer predisposition. The emerging picture is that breast and
ovarian cancer risks in BRCA1 and BRCA2 carriers are substan-
tially higher than in the general population, but that they are
considerably affected by nongenetic, environmental factors, and by
additional genetic modifiers.
BREAST AND OVARIAN CANCER RISK IN WOMEN
Original estimates of breast and ovarian cancer risks in carriers
were based on the families used for positional cloning of the
BRCA1 and BRCA2 genes, where all carriers had molecular testing,
and all cancer diagnoses were validated. These families were
chosen because they harboured multiple, early-onset cases, that is,
they were essentially selected for high cancer risk. In the Breast
Cancer Linkage Consortium (BCLC) families, by age 70 years,
BRCA1 carriers had a breast cancer risk of 71% (95% CI 53–82%)
and an ovarian cancer risk of 47–63% (Easton et al, 1995). BRCA2
carriers had a breast cancer risk of 84% (95% CI 43–95%), and an
ovarian cancer risk of 27% (95% CI, 0–47%) (Ford et al, 1998).
Many subsequent studies were case-based, that is, risk was
estimated by analysis of family history in relatives of breast or
ovarian cancer patients, often from hospital-based series (Anto-
niou et al, 2003). The design of these studies partially addressed
the ascertainment bias inherent in studying highly selected,
multiple-case families, but risk estimates were based on family
history, rather than on testing carriers directly and validating their
cancer status. With this design, misclassification can result from
discrepancies between modelled vs true carrier status, and from
errors in cancer reporting by relatives, a particularly common
problem for ovarian cancer. In a meta-analysis of such case-based
studies, by age 70 years, in BRCA1 carriers breast cancer risk was
65% (95% CI 51–75%) and ovarian cancer risk was 39% (95% CI
22–51%), and in BRCA2 carriers breast cancer risk was 45% (95%
CI 33–54%) and ovarian cancer risk was 11% (95% CI 4.1–18%)
(Antoniou et al, 2003). One study, performed in American
Ashkenazi Jews (AJ), combined ascertainment of unselected breast
cancer cases with direct genetic testing and clinical status
validation in relatives (King et al, 2003). By age 70 years, for
BRCA1 carriers, breast cancer risk was 69% (SE 5%) and ovarian
cancer risk was 46% (SE 6%), and for BRCA2 carriers, breast
cancer risk was 74% (SE 8%) and ovarian cancer risk was 12%
(7%). These risks continue to rise at older ages, reaching B80%
for breast cancer at age 80 years (Easton et al, 1995; Ford et al,
1998; King et al, 2003). Thus, point estimates of risk are somewhat
lower in case-ascertained, rather than family-ascertained studies,
but because of the large confidence intervals, substantial overlap
exists and many differences are not statistically significant.
However, if ‘true’ risk estimates are those for any carrier in the
population, even case-ascertained studies may be biased, because
the very occurrence of cancer in a carrier suggests that other
breast/ovarian cancer risk factors will be over-represented in her
relatives, leading to overestimation of risk in carriers (Begg, 2002).
These biases can be fully addressed only by population-based
studies, which currently are technically feasible only in ethnic
groups with founder mutations, for example, AJ and Iceland,
where a few, easily tested mutations account for practically all
deleterious changes in BRCA1 and BRCA2. A study of 5318 AJ
volunteers identified 120 carriers (93 cancer free), and estimated
cancer risk by comparing their family history with that of non-
carriers (Struewing et al, 1997). Cancer risks were similar in
BRCA1 and BRCA2 carriers, and by age 70 years breast cancer risk
was 56% (95% CI 40–73%), and ovarian cancer risk was 16% (95%
CI 6–28%). While breast cancer risk is in range of other estimates,
ovarian cancer risk is substantially lower, perhaps because of
unverified family history. Also, cancer rates in non-carriers were
relatively high in this study, which may have led to deflated risk
estimates based on comparing carriers to non-carriers. Discussing
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and BRCA2 carriers is beyond the scope of this review, but we
would like to address the variability of risk estimates in the
literature. Some of the variation is clearly methodological: family-
based studies are prone to ascertainment bias, and almost all case-
and population-based studies performed so far could be prone to
misclassification of genetic and clinical status. However, some of
the variation is likely due to true biological causes, including
effects of specific mutations (allelic effects), other genetic factors,
and nongenetic, environmental influences. The assumption is that
in sufficiently large studies these variations would be equally
distributed and risk estimates would remain comparable, but
sample sizes are not large in all studies, and some risk-affecting
factors can differ significantly, especially when studies are
performed in specific ethnic groups or in different countries.
EFFECTS OF SPECIFIC MUTATIONS
BRCA1 and BRCA2 are large genes, with thousands of different
mutations. A clear genotype–phenotype correlation exists for
BRCA2 mutations, where the central part of the gene (nt 3035–
6629 in exon 11) is named the ovarian cancer cluster region
(OCCR) because mutations within it are associated with an
increased ovarian : breast cancer ratio. Compared to other BRCA2
mutations, OCCR mutations are associated with higher ovarian
cancer risk (RR¼1.88; 95% CI 1.08–3.33) and lower breast cancer
risk (RR¼0.63; 95% CI 0.46–0.84) (Thompson and Easton, 2001).
Similar studies on BRCA1 mutations are less conclusive, but
suggest that mutations in the central part of the gene (nt 2401–
4190) are associated with lower breast cancer risk (RR¼0.71; 95%
CI 0.58–0.86), and that mutations in the 30 end (beyond nt 4191)
could be associated with lower ovarian cancer risk (RR¼0.81; 95%
CI 0.66–1.00) (Thompson and Easton, 2002). Most studies have
not taken these general genotype–phenotype correlations into
account. Furthermore, specific mutations could have unique risk
profiles, and their relative prevalence in different studies could
affect final risk estimates. In this context, one should note the
locations of the common AJ and Icelandic mutations, which
constitute a substantial fraction of carriers in many studies. In
BRCA1, the common Jewish 185delAG and 5382insC mutations are
outside the low breast cancer risk central region, and 5382insC is
within the low ovarian cancer risk region. In BRCA2, the common
Jewish mutation, 6174delT, is within the OCCR, whereas the
common Icelandic mutation, 999del5, is outside the OCCR.
OTHER GENETIC FACTORS – GENETIC MODIFIERS
The phenotypic expression of inherited disease can vary widely
even between individuals with the same disease-causing mutations,
as a result of both nongenetic variation and polymorphisms/
mutations in other genes, known as genetic modifiers. There is
epidemiological evidence for the existence of such modifiers for
BRCA1 and BRCA2 mutations, since there is familial clustering of
the cancer site: carriers in families with ovarian cancer index cases
are at higher risk for ovarian cancer and at lower risk for breast
cancer than carriers from families with breast cancer index cases
(Easton et al, 1995; Antoniou et al, 2003; Simchoni et al, 2006). In
the case of multiple generation families with different environ-
ments, familial clustering is likely to represent sharing of genetic
modifiers within families. The search for genetic modifiers was
originally limited to candidate genes, especially genes related to
hormone metabolism and pathways involving BRCA1 and BRCA2.
Length of repeat variations in the androgen receptor gene and in
the steroid nuclear receptor coactivator AIB1/NCOA3 were
reported to affect breast cancer risk (reviewed in Narod, 2002a),
but this has not been confirmed (Spurdle et al, 2005, 2006). A
noncoding polymorphism in RAD51, which binds BRCA2 in the
DNA repair process, has been shown to increase breast cancer risk
in BRCA2 carriers (HR¼3.2 5.5) in three independent studies,
all performed in AJs (discussed in Simchoni et al, 2006). There
has been one report of an HRAS-linked polymorphism affecting
ovarian cancer risk in BRCA1 carriers, but no follow-up studies
were published (Narod, 2002a). Thus, the only confirmed genetic
modifier is RAD51 in AJ BRCA2 carriers. Whole genome analysis
strategies are now being applied and may yield significant genetic
modifiers. Because genetic modifiers are yet to be identified, they
have not been accounted for in current risk-estimate studies.
NON-GENETIC EFFECTS
There are very significant nongenetic effects on breast and ovarian
cancer risk in BRCA1 and BRCA2 carriers. This is evidenced by the
consistent observation of increasing breast and ovarian cancer
risks in carriers born in more recent years (Antoniou et al, 2003;
King et al, 2003), although they carry the same mutations (and
genetic modifiers). For example, an RR of 7.7 (95% CI 2.6–23) for
breast cancer risk was found in BRCA1 carriers born from 1960
on, compared to those born before 1920 (Antoniou et al, 2003).
Further environmental influences are suggested by the effect of
country of origin on cancer risk (Antoniou et al, 2003).
Investigation of specific nongenetic factors has focused on factors
known to affect risk for sporadic breast and ovarian cancer, for
example, reproductive behaviour, hormonal exposure, and lifestyle
habits (Narod, 2002a; Dumitrescu and Cotarla, 2005). Risk
reduction surgeries (salpingo-oophorectomy and mastectomy)
are commonly offered to carriers, and result in substantial,
nongenetic decrease in breast/ovarian cancer risk. They are not
discussed here, since most studies censor carriers at the time of
first preventive surgery.
Reproductive factors
Age at menarche Younger age at menarche is associated with
increased risk for sporadic breast cancer. An effect was not
observed in BRCA2 carriers, but BRCA1 carriers whose age at
menarche was 14–15 years had a 54% reduction in breast cancer
risk compared to those with menarche at p11 years of age
(OR¼0.46, 95% CI 0.30–0.69) (Kotsopoulos et al, 2005).
Pregnancy Increased parity is protective for sporadic breast
cancer beyond age 40 years, but may increase risk for early-onset
breast cancer. In BRCA1 and BRCA2 carriers, parity effects may
also be age dependent. While an early report suggested that parity
may increase risk for early onset (o40years) breast cancer in
BRCA1 carriers (Narod, 2002a), a larger retrospective study of
1260 carrier pairs by the same group did not confirm this finding,
and even observed decreased breast cancer risk in BRCA1 carriers
with Xfour children (OR¼0.62, 95% CI 0.41–0.94, vs nulliparous
carriers) (Cullinane et al, 2005). In BRCA2 carriers, this study
found that parity caused a borderline increase in risk for breast
cancer before age 50 years (OR¼1.17 for each pregnancy, 95% CI
1.01–1.36) (Cullinane et al, 2005). In a case-only study, young age
at first pregnancy delayed onset of breast cancer in carriers (King
et al, 2003), and a retrospective study of 1601 carriers found that
in women over 40 years of age, each full-term pregnancy reduced
breast cancer risk by 14% (95% CI 6–22%). An age effect was seen
in that BRCA2 carriers with later first pregnancies had increased
risk, whereas BRCA1 carriers with first birth over age 30 years were
at lower risk than those with first birth before age 20 years
(Andrieu et al, 2006a). Overall, the effect of parity on breast cancer
in carriers is similar to that in sporadic cases.
Breast feeding In a case–control study of 965 BRCA1 and 280
BRCA2 pairs, breast feeding did not influence breast cancer risk in
BRCA2 carriers, but BRCA1 carriers who breast fed for over 1 year
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breast fed (OR¼0.55, 95% CI 0.38–0.80) (Jernstrom et al, 2004).
The retrospective cohort study of 1601 carriers did not show any
breast feeding effect (HR¼0.89, 95% CI 0.62–1.27) (Andrieu et al,
2006a).
Hormonal exposures – oral contraceptives (OC) The effect of OC
on breast cancer risk in carriers is difficult to assess because of
changing patterns of use and OC formulations with time. In a
retrospective case–control study of 981 BRCA1 and 330 BRCA2
carrier pairs, there was no effect of OC on breast cancer risk in
BRCA2 carriers, but in BRCA1 carriers risk for early-onset (o40
years) breast cancer was increased in women who first used OC
before 1975 (OR¼1.42, 95% CI 1.17–1.75), who used OC before
age 30 years (OR¼1.29, 95% CI 1.09–1.52), or who used them
for 5 or more years (OR¼1.33, 95% CI 1.11–1.60) (Narod et al,
2002b). Two recent studies based on early-onset breast cancer
cases, including small numbers (o100) of carriers, found no
general increase in breast cancer risk with OC use. One study
found increased breast cancer risk only with teenage (o20years)
OC use (OR¼1.53 (95% CI 1.17–1.99) per year of use at age o20
years) (Jernstrom et al, 2005), and in the others there was even a
suggestion of decreased breast cancer risk within BRCA1 carriers
(OR¼0.22, 95% CI 0.1–0.49 for OC use of at least 1 year) (Milne
et al, 2005). Altogether, these studies suggest that for breast cancer
risk, OC have similar relative effects in carriers and non-carriers.
These effects may be attenuated in newer, low-dose preparations,
but the absolute effect may be higher in carriers. OC use is known
to decrease ovarian cancer risk in the general population, and
similar effects have been seen in most studies of carriers (Narod,
2002a). In a case–control study, ovarian cancer risk was reduced
by 15% (OR¼0.85, 95% CI 0.53–1.36) with at least 1 year of OC
use, and by 38% with 6 years or more of OC use (OR¼0.62, 95%
CI 0.35–1.09) (Whittemore et al, 2004).
Physical activity and body weight Most of the evidence suggests
that in women at average risk, physical activity, and lack of obesity
are protective against breast cancer. In a study of 48 unaffected
carriers and 89 carriers with breast cancer, physical activity was
not protective (Nkondjock et al, 2006), but caloric intake in the
highest vs the lowest tertile increased breast cancer risk (OR 2.76,
95% CI 1.10–7.02). A larger case-only study found that increased
physical activity and lack of obesity in adolescence were associated
with significantly delayed breast cancer onset in BRCA1 and
BRCA2 carriers (King et al, 2003).
Radiation exposure Early radiation exposure increases breast
cancer risk, raising the concern that early screening mammogra-
phy in carriers may be harmful. In a case–control study of 3200
carriers, previous mammography did not increase breast cancer
risk (OR 1.03, 95% CI 0.85–1.25) (Narod et al, 2006). In contrast, a
retrospective cohort study of 1601 carriers found that any
exposure to chest X-rays was associated with an increased breast
cancer risk (HR¼1.54; P¼0.007). Risk was increased in carriers
aged 40 years and younger (HR¼1.97; Po0.001), particularly
those exposed only before the age of 20 years (HR¼4.64;
Po0.001) (Andrieu et al, 2006b). Further studies may determine
if these results imply differential effects of dose and developmental
timing of radiation exposure.
While fewer factors seem to significantly influence BRCA2-
compared to BRCA1-related risks, this could be the result of
smaller sample sizes of BRCA2 carriers and subsequent lack of
power. The demonstration of multiple nongenetic effects on cancer
risk in carriers requires controlling for these factors in risk
assessment. Year of birth is now commonly included in risk
models, but is unlikely to account for all environmental effects.
MALE-SPECIFIC CANCER RISKS – MALE BREAST AND
PROSTATE CANCER
Data on male-specific cancer risks are much more limited than on
female-specific cancer risks.
Male breast cancer (MBC) is a major characteristic of the
BRCA2-associated cancer syndrome. Cumulative risk for this
malignancy was assessed in 164 BRCA2-BCLC families, which
included 59 cases of male breast cancer, and risk was estimated at
2.8% (95% CI 0.6–13.0%) by age 70 years, rising to 6.9% by age
80 years (95% CI 1.2–38.6%) (Thompson and Easton 2001). This
corresponds to a RR of B80-fold. Mutation location (within or
outside the OCCR) does not influence MBC risk (Thompson and
Easton, 2001). While BRCA1 carriers are at lower risk than BRCA2
carriers, they seem to be at increased risk compared to the general
population. Cumulative MBC risk in BRCA1 carriers has been
estimated at 5.8% (95% CI 1.3–10.4%) over the entire lifetime (to
age 480 years), a figure based on four cases among 102 male
carriers in a clinic-based study (Brose et al, 2002). In studies of
MBC cases, the rate of BRCA1 mutations has been 3.2–10.4%
(reviewed by Liede et al, 2004) significantly higher than the
background rate.
Prostate cancer risk is also higher in BRCA2 compared to
BRCA1 carriers. Cumulative prostate cancer risk assessed in 173
BCLC-BRCA2 families was 7.5% (95% CI 5.7–9.3%) by age 70
years, corresponding to a RR of 4.65 (95% CI 3.48–6.22), which
may include a detection bias. A Dutch study of BRCA2 carriers
reached similar conclusions, with a cumulative risk of 5.2% (95%
CI 1.7–8.7%) by age 70 years, reflecting an RR of 2.5 (95% CI 1.6–
3.8) (van Asperen et al, 2005). BCLC family-based studies found
that prostate cancer risk in BRCA2 carriers depend on age and
BRCA2 mutation location. Relative prostate cancer risk was higher
in men younger than 65 years (RR¼7.3 (95% CI 4.7–11.5) than in
older men (RR 3.4 (85% CI 2.3–4.9) (The BCLC, 1999), and
mutations outside the OCCR were associated with higher risks
(33.6% (95% CI 25.1–44.1%) by age 80 years) than mutations
within the OCCR (19.2% (95% CI 10.7–33.1%) by age 80 years)
(Thompson and Easton, 2001). The lower risk in OCCR mutations
(OR¼0.52, 95% CI 0.24–1.00) may explain why prostate cancer
risk has not been consistently elevated in studies of BRCA2 in AJ
(Liede et al, 2004). It is less clear whether BRCA1 mutations
increase prostate cancer risk. In the BCLC-BRCA1 families, there
was some evidence of an increased risk of prostate cancer for men
younger than 65 years (RR 1.82, 95% CI 1.01–3.29), but not for
those aged 65 years or older (RR¼0.84, 95% CI 0.53–1.33)
(Thompson and Easton, 2002). Studies in AJ have yielded
conflicting results, but in general BRCA1 mutations have a limited
contribution to prostate cancer risk in this population (Liede et al,
2004).
RISK FOR OTHER CANCERS
In addition to breast and ovarian cancer in women, and breast and
prostate cancer in men, BRCA1 and BRCA2 carriers may be at
higher risk for additional malignancies. However, the absolute
risks for specific cancers at other sites are small (Gruber and
Petersen, 2002; Thompson and Easton, 2002). Risk for malig-
nancies at other sites has so far been addressed using two designs:
family-based studies, which compare the observed vs expected
number of cases of a specific malignancy, and studies which
compare rates of BRCA1/BRCA2 mutations in unselected cases of
a specific malignancy with mutation rates in controls or in the
general population. In family-based studies, diagnoses other than
breast or ovarian cancer were confirmed by pathology or clinical
records in only about half of the cases (The BCLC, 1999,
Thompson and Easton, 2002; van Asperen et al, 2005), whereas
in studies of mutation rates in specific cancers, all cases are
confirmed by pathology records. This is an important issue when
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Thus, reports of possible excess risk of other gynaecological
cancers (e.g. cervix and uterus), and gall bladder and bile duct
cancer may represent misclassifications of ovarian and pancreatic
cancer, respectively, and liver and bone cancers may represent
distant metastases from other sites.
Colon and rectal cancer risk was originally thought to be higher
in BRCA1, but not BRCA2 carriers (The BCLC, 1999; Thompson
and Easton, 2002). However, in the largest family-based study,
combined colorectal cancer risk was not increased (Gruber and
Petersen, 2002) and a large study of 225 unselected AJ colon cancer
cases did not find increased rates of BRCA1 or BRCA2 mutations
(Niell et al, 2004). Malignant melanoma, both cutaneous and
ocular, has been reported in BRCA2 families, and an excess risk
has been reported in the BRCA2-BCLC families (The BCLC, 1999).
This has not been confirmed in a smaller Dutch study (van
Asperen et al, 2005), and studies of unselected uveal melanoma
cases have not shown excess rates of BRCA2 mutations (Hearle
et al, 2003). Taken together, this suggests that melanoma risk may
be elevated in specific BRCA2 families, but not for all BRCA2
carriers.
Pancreatic cancer is currently the only additional malignancy for
which there is unequivocal evidence for increased risk in BRCA1
and BRCA2 carriers, although the absolute risk is small. In BRCA1
carriers pancreatic cancer risk carriers by age 70 years has been
estimated to be 1.16% (95% CI 0.83–1.61%) in men, and 1.26%
(95% CI 0.92–1.72%) in women, reflecting a two-fold RR
(Thompson and Easton, 2002). In BRCA2 carriers, the largest
study is that of the BCLC which included data on 566 malignancies
other than breast or ovarian cancers. This study estimated
pancreatic cancer risk in BRCA2 carriers by age 70 years to be
2.1% (95% CI 1.2–3.0%) in men, and 1.5% (95% CI 0.9–2.1%) in
women, reflecting a combined RR of 3.51 (95% CI 1.87–6.58) (The
BCLC, 1999). A smaller Dutch study, based on 199 malignancies
other than breast or ovarian cancer, estimated pancreatic cancer
risk in BRCA2 carriers by age 70 years at 4.1% (95% CI 1.0–7.3%)
in men and 1.4% (95% CI 0–3.4%) in women (Van Asperen et al,
2005). These risk estimates are also consistent with the 4–7% rate
of BRCA1 and BRCA2 mutations among unselected pancreatic
cases (reviewed in Liede et al, 2004).
CONCLUSION
Breast and ovarian cancer risk in BRCA1 and BRCA2 carriers is a
complex trait, affected by genetic modifiers and nongenetic
factors. While further studies are necessary to define and quantify
risk-factor effects, even now the best approach for the individual
patient is perhaps a personalised one, which takes into account
family history, ascertainment, and known environmental risk
factors.
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